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Objective: Aneurysms or dissections can involve multiple aortic segments in patients with Marfan syndrome,
requiring staged replacement of the entire aorta. The optimal treatment of descending aortic dissection in these
patients is a major challenge. We investigated the feasibility and outcomes of endovascular repair of the descend-
ing aorta in patients already submitted to open aortic root/arch surgery.
Methods: From March 1998 to July 2008, 12 patients (10 male and 2 female patients; mean age, 37.8  11.6
years) affected by Marfan syndrome underwent endovascular treatment for dissection of the descending aorta
after previous open aortic root/arch surgery. Stent graft procedures were performed urgently in 5 patients and elec-
tively in 7 patients.
Results: Neither in-hospital deaths nor perioperative paraplegia or stroke occurred. Follow-up (median, 31
months; range, 3–57 months) was 100% complete. One patient needed surgical conversion for persistent type
I endoleak, leading to false lumen expansion 3 months after endovascular repair. Extension of the dissection
occurred in 2 patients 1 month and 2 years after the procedure, respectively. No late death or aortic rupture
was observed.
Conclusions: Endovascular repair of the dissected descending thoracic aorta can be performed in patients with
Marfan syndrome with a low risk of death or major complications. In case of staged procedures, stent graft treat-
ment can be considered a possible alternative to open reoperation. Long-term durability remains to be determined.
Acquired Cardiovascular Disease Botta et alMarfan syndrome is a relatively common heritable disorder
of connective tissue that affects numerous organ systems,
but the most severe complication is aortic aneurysm and dis-
section.1-3 Aneurysms or dissections can frequently involve
multiple aortic segments, requiring staged replacement of
the entire aorta.3-5 Although progress of surgical techniques
for the ascending aorta improved life expectancy in patients
with Marfan syndrome,5-7 results of conventional surgical
intervention or medical treatment for descending aortic dis-
section are still disappointing.8-11 The feasibility of endovas-
cular aortic repair provided new alternatives, but the
potential risks are not fully determined. The aim of this study
was to analyze procedural feasibility, early and midterm re-
sults, and clinical outcome after endovascular aortic repair of
the descending aorta in 12 consecutive patients with Marfan
syndrome already submitted to open aortic root/arch
surgery.
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Patients
From March 1998 to July 2008, 115 patients underwent endovascular re-
pair for dissection of the descending aorta. Of these, 12 (10.4%) patients
were affected by Marfan syndrome according to the Ghent nosology. There
were 10 male and 2 female patients (mean age, 37.8  11.6 years). The
mean American Society of Anesthesiologists class was 3.2  0.7. Patient
characteristics are shown in Table 1.
Thoracic Aortic Involvement and Previous Aortic
Surgery
All patients have been previously submitted to open aortic surgery for
annuloaortic ectasia (4 Bentall procedures and 1 ‘‘David 1’’ operations)
and acute (2 Bentall procedures and 3 supracoronary replacements) and
chronic (1 Bentall procedure and 1 ‘‘David 1’’ operation) type A aortic dis-
section. Hemiarch or total arch replacement was performed in 5 and 4 pa-
tients, respectively. The elephant trunk technique was used in 3 patients.
A mitrotricuspid valve plasty was associated with a Bentall procedure in
1 patient. In the same patient an orthotopic heart transplantation was per-
formed for end-stage cardiomyopathy 10 years later. Three patients who un-
derwent the Bentall procedure plus hemiarch replacement (1 patient) and
supracoronary replacement plus hemiarch replacement (2 patients) for acute
type A dissection underwent reoperations for aneurysmal degeneration of
the aortic arch.
Presenting Signs, Symptoms, and Interventional
Indications
A classical type B aortic dissection with an abrupt onset of pain was di-
agnosed in 5 (41.7%) patients, all previously submitted to aortic root
surgery for aneurysm a median of 168 months (range, 24–264 months)
previously. Chest pain was reported by all patients, whereas abdominal
and leg pain was experienced by 2 and 1 patients, respectively. Preoperative
acute malperfusion was detected in 3 patients (mesenteric ischemia,rgery c November 2009
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CT ¼ computed tomography
MRI ¼ magnetic resonance imaging
TEE ¼ transesophageal echocardiography
acute renal failure, and limb ischemia in 1 patient each). Preoperative hyper-
tension appeared at presentation in 4 of 5 patients. No patient was admitted
with shock or tamponade, but left hemothorax was found in 4 patients. En-
dovascular repair was indicated in the acute phase for an impending aortic
rupture in 2 (16.7%) patients and for visceral or limb ischemia in 2 and 1
patients, respectively. In chronic cases (7 patients) indications were the in-
creasing diameter of the descending aorta during follow-up (all) and recur-
rent pain (4 patients).
Diagnostic Evaluation
Routine examination of heart, lung, liver and kidney functions, as well as
contrast-enhanced computed tomographic (CT) analysis, magnetic reso-
nance imaging (MRI), and/or angiographic analysis, were conducted both
in emergency and elective cases. Hemodynamically compromised patients
underwent only CT scanning just before emergency/urgent stent graft re-
pair. Anatomic assessment of the descending aorta was made by using 1
or more imaging methods, including CT scanning in 83.3%, aortographic
analysis in 75%, and MRI in 33.3%. Preoperative chest radiographic anal-
ysis was performed in all patients and showed a widened mediastinum in
100%. Tomographic imaging revealed pleural effusion in 33.3% of patients
and a periaortic hematoma in 8.3% of patients, with signs of free rupture in
1 patient. Aortic measurements were performed in multiple planes perpen-
dicular to the major vessel axis. At least 5 to 10 measurements were per-
formed at the neck sites in patients undergoing elective operations. The
mean aortic diameter of the pseudoaneurysm was 51.1  3.8 mm.
Stent Graft Procedure
Patients underwent mechanical ventilation after achievement of general
anesthesia. Blood pressure was monitored by means of right radial artery
cannulation. Ceftriaxone (2 g administered intravenously) was administered
before the procedure. The common femoral artery was used for access after
surgical exposure in all patients. After exposition of the artery, a 6F sheath
was inserted, and 2500 IU of heparin was administered. In patients with ac-
tive bleeding into the pleural space, mediastinal space, or both, no systemic
heparin was administered. Angiographic analysis and transesophageal
echocardiographic (TEE) analysis were performed to identify the lesion
and landing zones and the lesion’s relation to side branches in all patients.
Twenty-nine thoracic stent grafts (21 Talent and 8 Valiant; Medtronic, Santa
Rosa, Calif) were loaded on an extrastiff guidewire and delivered under
fluoroscopic and TEE control with induced hypotension (systolic pressure,
<70 mm Hg) to prevent inadvertent downstream displacement of the stent
graft during delivery. The proximal end of endografts was always an uncov-
ered stent (free-flow end). On the basis of CT/MRI/TEE measurement,
a maximum oversizing of 10% was applied in the choice of stent graft di-
ameter. A shaping balloon was used when necessary under TEE control. An
elephant trunk was used as the landing zone of the endografts in 3 patients.
Postprocedural angiographic and TEE controls were performed to reveal the
final result. There were no local complications related to the presence of the
sheath, and no thrombectomies were performed in any case. No aortic fen-
estration was necessary in this series. Intraoperative details are reported in
Table 2.
Statistical Analysis
All statistical analyses were performed with the SPSS software package
(version 14.0; SPSS, Chicago, Ill). Incidence rates of events are reported asThe Journal of Thoracic and Cathe number of patients experiencing the event followed by the correspond-
ing percentage. Continuous data are reported as the mean  standard devi-
ation, median and range, or both of values observed. The Kaplan–Meier
actuarial method was used to generate survival estimates and freedom
from endoleaks and from reoperation reported with 95% confidence limits.
RESULTS
Technical success (insertion and deployment of the stent
graft in the target aortic segment) was achieved in all pa-
tients. More than 1 stent was necessary in 11 (91.7%) of
12 patients. One stent graft was implanted in 1 patient, 2
stent grafts each were implanted in 5 patients, and 3 stent
grafts each were implanted in 6 patients, according to the
number and site of re-entries. The need for 2 or 3 stents is
related to many factors, both anatomic and physiopatho-
logic: the extent of the disease, the presence of multiple large
re-entry sites (the clinical relevance of which is evident only
after deployment of first grafts), the length of the thoracic
aorta (related to body surface area), and the necessity to
land in a safe proximal zone (usually more proximal than
in standard procedures) or inside a previous vascular graft.
Neither intraoperative mortality nor surgical conversion oc-
curred. Postoperatively, 5 (41.7%) patients were transferred
to the intensive care unit, and 7 were transferred directly to
the ward after extubation in the operating room. The median
intubation time was 2.5 hours (range, 1–13 hours). Median
intensive care unit and in-hospital stays were 20 hours
(range, 6–21 hours) and 9 days (range, 2–19 days), respec-
tively. Only 1 patient received blood cell transfusion. In
all patients blood pressure was tightly controlled (systolic
blood pressure,<120 mm Hg). Fever, increased C-reactive
TABLE 1. Patients’ preoperative features
Age (y)  SD 37.8  11.6
Sex (male/female) 10/2 (83.3/16.7)
NYHA classification
I–II 10 (83.3)
III–IV 2 (16.7)
ASA class  SD 3.2  0.7
Presentation of type B aortic dissection
Acute 5 (41.7)
Chronic 7 (58.3)
Hemothorax 4 (33.3)
Hypertension 4 (33.3)
Smokers 4 (33.3)
COPD 1 (8.3)
Diabetes 1 (8.3)
Renal failure 3 (25)
Previous cardiac/aortic surgery 12 (100)
Aortic measures
Aortic diameter (mm)  SD 51.1  3.8
Values are presented as the mean  standard deviation or the number of patients ex-
periencing the event followed by the corresponding percentage in parentheses, unless
otherwise noted. SD, Standard deviation; NYHA, New York Heart Association func-
tional class; ASA, American Society of Anesthesiologists; COPD, chronic obstructive
pulmonary disease.rdiovascular Surgery c Volume 138, Number 5 1109
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Patient
no. PAO
Time
between
PAO and
EVAR (mo)
Technical
success
Surgical
access
Left
subclavian
artery
closure
Stent
grafts
per
patient
Endograft
diameters
Stent
graft
length
Fluoroscopic
time
Contrast
media
Surgical
conversion Transfusions Mortality
1 Reimplantation 24 Y RCFA N 2 32/26 30/30 105
116
25 110 Y N N
2 Bentall 264 Y RCFA N 1 24/30 151 12 120 N N N
3 Ascending
aortic
replacement
41 Y RCFA N 3 30/30 34/30 32/32 115
113
115
32 120 N N N
4 Bentall
procedure
108 Y LCFA N 3 32/32 34/30 36/32 115
113
112
18 100 N Y N
5 Reimplantation
þarchþET
2 Y RCFA N 3 32/32 36/36 38/38 100
150
114
25 100 N N N
6 Bentall procedure 168 Y RCFA N 2 36/32 34/30 112
113
12 90 N N N
7 Ascending
aortic
replacement
20 Y RCFA N 2 36/32 34/30 112
113
10 70 N N N
8 Bentall
procedure
þMVPþTVP
168 Y RCFA Y 3 32/32 36/32 34/34 200
150
48
25 210 N N N
9 Ascending
aortic
replacement
þarch
58 Y RCFA Y* 2 30/30
34/30
200
150
14 100 N N N
10 Bentall
procedure
þarchþET
66 Y RCFA N 3 28/28
32/28
32/28
150
150
150
100 90 N N N
11 Bentall procedureþ
ArchþETþMVR
2 Y RCFA N 2 32/32
36/32
200
150
40 110 N N N
12 Bentall procedure 408 Y RCFA N 3 30/30
34/34
34/34
200
100
200
19 180 N N N
Values are presented as absolute numbers. PAO, Previous aortic operation; EVAR, endovascular aortic repair; Y, yes; RCFA, right common femoral artery; N, no; LCFA, left com-
mon femoral artery; ET, elephant trunk; MVP, mitral valve plasty; TVP, tricuspid valve plasty; Y*, yes with previous left subclavian artery–left common carotid artery bypass;MVR,
mitral valve replacement.protein levels, and leucocytosis were observed in all patients
starting from the first postoperative day in the absence of any
evident infectious agent. The systemic inflammatory re-
sponse was mild and self-limiting in the majority of patients,
lasting from 2 to 10 days and responding to nonsteroidal
anti-inflammatory drug administration, but it was prolonged
in 3 patients (from 15 days to>3 months) without leucocy-
tosis, positive blood culture results, or both.
One patient required a femorofemoral bypass 24 days after
endovascular repair for acute limb ischemia caused by distal
extension of the dissection. Early type II endoleaks caused by1110 The Journal of Thoracic and Cardiovascular Sua backflow from an intercostal artery (1 patient) and from the
left subclavian artery after intentional closure without previ-
ous revascularization (1 patient) were detected in 2 patients.
Both endoleaks resolved spontaneously within 6 to 12
months. Type I endoleak, leading to aneurysmal expansion,
was detected in 1 patient who was converted to surgical in-
tervention 3 months later. A left thoracotomy was performed
to remove the stent graft, and an interposition vascular graft
was used in the thoracic aorta without serious complications.
Neither paraplegia nor other perioperative complications
occurred. In-hospital results are summarized in Table 3.rgery c November 2009
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which was 100% complete. The median follow-up time
was 31 months (range, 3–57 months). Clinical examination
and CT scan or MRI controls were performed at discharge;
at 1, 3/6, and 12 months after treatment; and every 12
months thereafter (Figure 1). Retrograde blood flow distal
to the implanted endograft and preventing the complete
thrombosis of the false lumen in the distal descending aorta
was observed in all patients at 1 to 3 months after the proce-
dure. However, a reduction of mean diameters of the in-
volved aortic segments and a progressive thrombosis of
the false lumen involving the entire thoracic aorta was usu-
ally observed after almost 6 months. Persistent false lumen
expansion of the distal descending thoracic aorta occurred
in 1 patient and was treated with a second endovascular pro-
cedure (stent graft extension) 38 months after the first proce-
dure. The second procedure was successful, and progressive
thrombosis of the false lumen in the thoracic aorta was ob-
tained. At last follow-up, the patient is in good general con-
dition without complications. A new dissection of the native
arch, interposed between a vascular graft proximally and the
endograft distally, was detected in 1 patient 2 years after the
procedure. The aortic diameter was less than 3 cm, and the
patient is currently in follow-up. No late deaths occurred
during follow-up. Actuarial freedom from endoleak and
from any type of reoperation is shown in Figures 2 and 3.
DISCUSSION
Marfan syndrome is an autosomal dominant disorder of
connective tissue characterized by highly variable clinical
manifestations, primarily in the skeletal, ocular, and cardio-
vascular organ systems. Mutation in the fibrillin gene is
TABLE 3. Early and midterm results
In-hospital results
Intubation time (h)* 2.5 (1–13)
ICU stay (h)* 20 (6–21)
In-hospital stay (d)* 9 (2–19)
Paraplegia 0
Stroke 0
Acute renal failure 0
Respiratory insufficiency 0
Early endoleak
Type I 1 (8.3)
Type II (R) 2 (16.7)
Late endoleak
Type I 1 (8.3)
Follow-up
Surgical conversion 1 (8.3)
Second endovascular procedure 1 (8.3)
New dissection during follow-up 2 (16.7)
Overall mortality 0
Values are presented as the number of patients experiencing the event followed by the
corresponding percentage in parentheses, unless otherwise noted. ICU, Intensive care
unit; (R), spontaneous resolution during follow-up. *Median (range).The Journal of Thoracic and Caresponsible for the alteration of extracellular matrix in the
connective tissue, leading to aortic dilation and dissec-
tion.1,12,13
Long-term surveillance of the aorta before and after surgi-
cal intervention and prophylactic resection of the dilated
segment has become standard practice in patients with Mar-
fan syndrome, prolonging survival similarly to that seen in
the healthy population.2,3 Excellent results have been ob-
tained in elective surgical intervention of the ascending aorta
with composite grafts and valve-sparing operations,6,7,14-17
whereas relatively low morbidity and mortality rates are ac-
tually associated with urgent or emergency procedures.14
Given the benefits of prophylactic aortic surgery, there are
a growing number of patients who might require secondary
aortic operations as a result of new or residual dissections,
increasing diameter, or new aneurysms.
All patients of our series underwent previous surgical in-
tervention of the ascending aorta, aortic arch, or both. Retro-
spective analysis of our data showed that patients undergoing
operations for aortic root aneurysm associated or not with
aortic valve disease had a new-onset type B dissection requir-
ing interventional treatment after a median of 14 years from
the first operation. On the other hand, patients treated for type
A aortic dissections underwent endovascular repair earlier
(2.5 years after the first operation). A close follow-up of all
patients with Marfan syndrome is necessary to detect asymp-
tomatic changes requiring repair.4,18 After aortic root re-
placement, aortic operations in the descending aorta are
required in 50% of patients over a mean period of 26 years.19
The risk of aortic dissection increases with increasing aortic
diameter, but it can also occur in nondilated aortas. Carrel and
colleagues4 reported a high incidence of reoperation in pa-
tients with acute type A aortic dissection, with unexpected fa-
tal outcome even if the aorta is normal sized. In contrast to the
aortic root, at present, no clear guidelines elucidate definite
criteria for descending aortic operations either for prophylac-
tic or urgent surgical repair.3,5,19 As a matter of fact, the op-
timal treatment for patients with acute or residual dissections
of the descending aorta continues to be debated. The progno-
sis for patients with type B aortic dissection is bleak and
determined primarily based on dissection-related and pa-
tient-specific risk factors.10,20-24 International Registry of
Acute Aortic Dissection investigators9 reported an overall
in-hospital mortality of 33.9% after conventional surgical in-
tervention for acute type B dissection. The actuarial survival
estimates for all patients were 71%, 60%, 35%, and 17% at
1, 5, 10, and 15 years, respectively, and were similar for the
medical and surgical patients.25 Reoperation and late aortic
complications were predicted by the presence of patients
with Marfan syndrome. Mortality is related either to retro-
grade progression of dissection with involvement of the
proximal aorta with even higher mortality or to expansion
of the false lumen and formation of a thoracic aneurysm
with an inherent risk of rupture.rdiovascular Surgery c Volume 138, Number 5 1111
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DFIGURE 1. Volume-rendering (A) and maximum-intensity projection (MIP) images (B) of the acute aortic type B dissection with the entry tear at the level of
the left subclavian artery ostium in a patient with Marfan syndrome initially operated on for an annuloaortic ectasia and proximal arch aneurysm. In panel A the
white arrow shows the vascular graft used for ascending aortic and arch replacement. Dissection of the descending aorta in axial projection is shown in panel
C. Volume-rendering (D) and MIP images (E) show a correct position of the stent graft and the absence of endoleak 3 months after the procedure; the white
asterisk indicates patency of the false lumen (FL) distally to the implanted graft. Panel F shows the complete thrombosis of the FL in the descending thoracic
aorta in axial projection after 3 months.1112 The Journal of Thoracic and Cardiovascular Surgery c November 2009
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fan syndrome is widely debated because of the potential risk
induced by radial forces of the stent graft on the fragile aortic
wall. Stent grafting into synthetic graft ‘‘necks’’ proximally
and distally might be a safer alternative than a repeat thora-
cotomy in selected cases. In their update on treatment of aor-
tic disease in patients with Marfan syndrome, Milewicz and
associates5 suggest that stent grafts should not be used in ei-
ther the abdominal or the thoracic aorta in patients with this
syndrome or other connective tissue diseases. Endovascular
stent grafts have been successfully used to treat persistent
distal aortic dissection after previous root replacement, as
reported by Ince and coworkers.26 In their series of 6 patients,
elective conversion to surgical repair was necessary in 2
patients at 22 and 43 months after stent graft implantation,
respectively, and was being considered at 74 months in a third
patient. Our experience showed acceptable results with low
morbidity rates and a low incidence of vascular complica-
tions and endoleaks. However, progression of dissection or
a new dissection, which often characterizes the course of
Marfan disease, might be accelerated by the effect of the stent
graft. In our series 2 patients presented with a new dissection
during follow-up: in 1 patient a new dissection of an inter-
posed aortic arch between a Dacron graft in the ascending
aorta and the stent graft in the descending aorta occurred sev-
eral months after the procedure; the clinical course was un-
eventful, and the patient is still in follow-up without
significant arch enlargement. The second case, a distal dis-
section of the descending aorta, occurred 24 days after the
procedure. According to retrospective case review, the dis-
section, which was adjacent to the distal part of the stent graft,
was probably related to an excessive oversizing with respect
to the aortic diameter.
FIGURE 2. Freedom from any type of endoleak.The Journal of Thoracic and CaDespite a minimal inflammatory cell infiltration described
at the level of the aortic wall in patients with Marfan syn-
drome,27 all patients of our series experienced a self-limiting
postimplantation syndrome in the postoperative period char-
acterized by fever and leucocytosis. The trigger of this sys-
temic reaction is unclear, but it is possible that endograft
materials and the remodeling of endovascular thrombus
could play an important role in the stimulation of the im-
mune response. Another peculiar finding in our experience
has been the presence of a large retrograde blood flow in
the false lumen distal to the implanted endograft, initially
preventing the immediate thrombosis of the false lumen,
probably because of larger re-entry sites than in patients
without Marfan syndrome. However, complete and endur-
ing thrombosis of the false lumen in the thoracic aorta was
observed almost 6 months after the procedure in all patients
without endoleak.28
CONCLUSION
Endovascular repair of the dissected descending thoracic
aorta can be performed in patients with Marfan syndrome,
with low risk of death and major complications. In case of
staged procedures, stent graft treatment can be considered
a possible alternative to open reoperation. Because of the par-
ticular fragility of the aortic wall in these patients, careful case
selection avoiding hostile anatomy (an excessive tortuosity of
the aorta, an angulated aortic arch or extension of the lesion to
the aortic arch, the presence of a graft in the abdominal aorta,
the presence of large entry or re-entry sites close to the celiac
trunk and a short proximal neck [<5 mm from left subclavian
artery], landing zones with a diameter of 42 or 20 mm,
and diameter of the femoral or iliac arteries of 8 mm),
FIGURE 3. Freedom from any type of reoperation (surgical and endovas-
cular).rdiovascular Surgery c Volume 138, Number 5 1113
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are mandatory to avoid potential complications. Long-term
durability remains to be determined. A strict follow-up is
necessary to detect possible failures.
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